Supply Chain

UPMC attempts to reduce supply chain expenses by using an electronic data interchange.

Genetic and genomic clinical laboratory testing generates 116,000 U.S. jobs and contributes $16.5 billion annually to the U.S. economy, according to a new report released Thursday by the Battelle Memorial Institute.

The market for stem cell technologies will rise to over $700 million this year, and given some positive trends, could reach over $1 billion, according to healthcare market research publisher Kalorama Information.

The U.S. market for orthopedic biomaterials will grow at an average of just under 7 percent per year, to total approximately $4 billion by 2016, predicts medical technology market research firm Millennium Research Group (MRG).

Contrary to federal law, CMS accepted $15.1 million in gross drug costs for prescriptions written by excluded providers from 2006 to 2008 under the Medicare Part D program, according to a recent report from the Office of Inspector General.

The U.S. Department of Justice announced late last week that GE Healthcare has paid more than $30 million to the government to settle False Claims Act allegations.

As drug shortages become more frequent and severe, providers are feeling the financial impact of the higher-priced alternatives and the personnel hours required to deal with the escalating problem.

Even though the Centers for Medicare & Medicaid Services has taken steps to curtail fraud and abuse from Medicare suppliers of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS), it needs to do more says a recently released report from the Office of Inspector General.

Healthcare real estate will continue to be a strong investment category in 2012 concludes an analysis by Jones Lang LaSalle, a financial and professional services firm specializing in real estate.

Pfizer received a flurry of attention toward the end of November as its blockbuster statin Lipitor came to the end of its patent protection.